Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure

Trial Profile

Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Heart Failure

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Nov 2018

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Heart failure; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms EMBRACE-HF
  • Most Recent Events

    • 05 Nov 2018 Planned End Date changed from 1 Jan 2019 to 1 Jun 2019.
    • 05 Nov 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2019.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top